PaxVax secures up to $62M, acquires typhoid vaccine

Vaccine company PaxVax Inc. (Redwood City, Calif.) secured up to $62 million comprising up to $50 million in debt from Pharmakon Advisors and $12 million in an extension of a series B round from undisclosed existing and new investors. PaxVax used part of the funds to acquire typhoid vaccine Vivotif from Johnson & Johnson (NYSE:JNJ) subsidiary Crucell N.V. and the vaccine's Swiss manufacturing facility. ...